Transforming ovarian cancer care by targeting minimal residual disease
Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Stefani Spranger(University of Chicago), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Dmitriy Zamarin(Tisch Hospital), Rachel N. Grisham(Memorial Sloan Kettering Cancer Center), Kai W. Wucherpfennig(Dana-Farber Cancer Institute), Stéphanie Gaillard(Sidney Kimmel Cancer Center), Sohrab P. Shah(Memorial Sloan Kettering Cancer Center), Barrett C. Lawson(The University of Texas MD Anderson Cancer Center), Britta Weigelt(Memorial Sloan Kettering Cancer Center), Alan D. D’Andrea(Dana-Farber Cancer Institute), Linghua Wang(The University of Texas MD Anderson Cancer Center), Enrico Moiso(Massachusetts Institute of Technology), Carol Aghajanian(Memorial Sloan Kettering Cancer Center), Ie‐Ming Shih(Johns Hopkins University), Anne Knisely(The University of Texas MD Anderson Cancer Center), Ursula A. Matulonis(Dana-Farber Cancer Institute), Paula T. Hammond(Broad Institute), Kathleen H. Burns(Massachusetts General Hospital), Panagiotis A. Konstantinopoulos(Dana-Farber Cancer Institute), R. Tyler Hillman(The University of Texas MD Anderson Cancer Center), Thomas R. Pisanic(Johns Hopkins University), Marc Williams(Memorial Sloan Kettering Cancer Center), Sanghoon Lee(Gyeongguk National University), Neelkanth M. Bardhan(Massachusetts Institute of Technology)
Cited by 5
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k